PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic TAMPA, Fla., Aug. 10, 2022 /PRNewswire/ — Psilera Inc. (“Psilera”), a biopharmaceutical company optimizing next-generation mental health treatments with a technology-enabled platform, announces promising results on two patent-pending N…


Previous articleMindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Next articleCan Psilocybin Treat Obesity? New Evidence, Future Directions